

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: RELTON <i>et al.</i> Appl. No.: 10/587,714 § 371 Date: June 4, 2007	Confirmation No.: 2306 Art Unit: 1646 Examiner: Sandra L. WEGERT Atty. Docket: 2681.0450001/EJH/JBF
For: Treatment of Conditions Involving Dopaminergic Neuronal Degeneration Using Nogo Receptor Antagonists	

Amendment and Reply Under 37 C.F.R. § 1.114

Mail Stop RCE

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

In reply to the Office Action dated April 14, 2010 (PTO Prosecution File Wrapper Paper No. 20100405), Applicants submit the following Amendment and Remarks.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks and Arguments begin on page 9 of this paper.

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net